Adaptive Biotechnologies Corp’s recent filing unveils that its Chief Financial Officer PISKEL KYLE unloaded Company’s shares for reported $17149.0 on May 16 ’25. In the deal valued at $8.89 per share,1,929 shares were sold. As a result of this transaction, PISKEL KYLE now holds 277,396 shares worth roughly $2.86 million.
Then, ROBINS HARLAN S sold 68,412 shares, generating $502,828 in total proceeds. Upon selling the shares at $7.35, the Chief Scientific Officer now owns 1,279,524 shares.
Before that, Harlan Robins bought 68,412 shares. Adaptive Biotechnologies Corp shares valued at $503,512 were divested by the Officer at a price of $7.36 per share.
Goldman upgraded its Adaptive Biotechnologies Corp [ADPT] rating to a Buy from a a Neutral in a research note published recently. Scotiabank began covering ADPT with “Sector outperform” recommendation on January 05, 2023. Piper Sandler revised its rating on December 21, 2022. It rated ADPT as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of ADPT
On Friday, Adaptive Biotechnologies Corp [NASDAQ:ADPT] saw its stock fall -0.86% to $10.32. Over the last five days, the stock has gained 2.28%. Adaptive Biotechnologies Corp shares have risen nearly 72.14% since the year began. Nevertheless, the stocks have risen 199.13% over the past one year. While a 52-week high of $10.87 was reached on 06/11/25, a 52-week low of $2.99 was recorded on 01/02/25.
Levels Of Support And Resistance For ADPT Stock
The 24-hour chart illustrates a support level at 9.99, which if violated will result in even more drops to 9.66. On the upside, there is a resistance level at 10.56. A further resistance level may holdings at 10.80.
How much short interest is there in Adaptive Biotechnologies Corp?
A steep rise in short interest was recorded in Adaptive Biotechnologies Corp stocks on 2025-05-30, growing by 0.5 million shares to a total of 9.64 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 9.14 million shares. There was a rise of 5.14%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 25, 2022 when Credit Suisse began covering the stock and recommended ‘”an Underperform”‘ rating along with a $8 price target.
